Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.

Journal of hematology & oncology - 21 Sept 2020

Ghelli Luserna di Rorà Andrea, Cerchione Claudio, Martinelli Giovanni, Simonetti Giorgia

Abstract excerpt

The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has recently gained interest, and different DDR inhibitors have been developed. Among them, the most promising ones target the WEE1 kinase family, which has a crucial role in cell cycle regulation and DNA damage identification and repair in both nonmalignant and cancer cells. This review recapitulates and discusses the most recent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemoradiotherapy
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Hematologic Neoplasms

Share to Mitosis

Share to Oncogenes

Share to Pyrazoles

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 32958072
DOI: 10.1186/s13045-020-00959-2
PMCID: PMC7507691

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.PMID 32958072Read ↗

Wee1 kinase as a target for cancer therapySemantic proximity Read ↗

Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitorsSemantic proximity Read ↗

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)Semantic proximity Read ↗

Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-γH2AX-MDC1Semantic proximity Read ↗

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in CancerSemantic proximity Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid TumorsSemantic proximity Read ↗

Molecular targets that sensitize cancer to radiation killing: From the bench to the bedsideSemantic proximity Read ↗

Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging AgentsSemantic proximity Read ↗

Targeting the DNA damage response in cancerSemantic proximity Read ↗

Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 InhibitionSemantic proximity Read ↗

Molecular Pathways: Targeting the Protein Kinase Wee1 in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.